Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › apixaban

apixaban

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of apixaban

51 trials tracked of apixaban: 24 in phase 3 or 4 and 12 with published results. The most-cited published study has 1058 citations.

51Trials tracked
24Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 4 9 Phase 3 15 Phase 2 8 Phase 1 7 Other / NA 12
  1. Phase 3 Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer Completed · 1,058 cited
  2. Phase 3 Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Completed · 589 cited
  3. Phase 4 Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Completed · 230 cited
  4. Phase 4 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) Completed · 172 cited
  5. Phase 3 Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy Completed · 56 cited
  6. Phase 3 A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase Completed · 53 cited
Show 44 more trials
  1. Phase 4 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed · 46 cited
  2. Phase 4 Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) Completed · 33 cited
  3. Phase 3 Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation Completed · 32 cited
  4. Phase 3 Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation Completed · 22 cited
  5. Phase 4 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Completed · 16 cited
  6. Phase 4 A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart Completed · 10 cited
  7. Phase 4 Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery Completed
  8. Phase 4 Apixaban Pharmacokinetics in Bariatric Patients (APB) Completed
  9. Phase 4 Apixaban for the Acute Treatment of Venous Thromboembolism in Children Completed
  10. Phase 3 AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients Completed
  11. Phase 3 RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding Completed
  12. Phase 3 Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3) Completed
  13. Phase 3 Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery Completed
  14. Phase 3 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed
  15. Phase 3 A Phase III Study of Apixaban in Patients With Atrial Fibrillation Completed
  16. Phase 3 Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed
  17. Phase 3 Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness Completed
  18. Phase 3 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation Completed
  19. Phase 2 Safety Study of Apixaban in Recent Acute Coronary Syndrome Completed
  20. Phase 2 Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices Completed
  21. Phase 2 A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects Completed
  22. Phase 2 A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer Completed
  23. Phase 2 Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT Completed
  24. Phase 2 A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation Completed
  25. Phase 2 Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications. Completed
  26. Phase 2 A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation Completed
  27. Phase 1 Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis Completed
  28. Phase 1 Bioavailability of Apixaban Crushed Tablet Completed
  29. Phase 1 Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects Completed
  30. Phase 1 A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects Completed
  31. Phase 1 Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects Completed
  32. Phase 1 A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects Completed
  33. Phase 1 Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects Completed
  34. N/A Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation Completed
  35. N/A Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea Completed
  36. N/A Medical Need of OAC Reversal Completed
  37. N/A Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data Completed
  38. N/A Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea Completed
  39. N/A Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare Completed
  40. N/A A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France Completed
  41. N/A Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer Completed
  42. N/A Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data Completed
  43. N/A Treatment Patterns Among Patients With Venous Thromboembolism in the United States Completed
  44. N/A Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf) Completed

Showing the 50 most-cited and recently-updated of 51 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
DOACs reduce thrombosis recurrence and major bleeding compared to warfarin in morbidly obese VTE patients
Diabetes & Endocrinology Meta-analysis
DOACs reduce thrombosis recurrence and major bleeding compared to warfarin in morbidly obese VTE patients DOACs Show Lower Risk of Blood Clots in Patients with Obesity
This meta-analysis of 44,672 patients found that DOACs are associated with lower risks of thrombosis recurrence (OR 0.74) and major bleeding…
New data suggests that direct acting oral anticoagulants may be more effective than warfarin for managing blood clots in patients with morbi…
NEJM Aug 22, 2026
NOAC monotherapy reduces net adverse clinical events in older patients with atrial fibrillation and stents
Cardiology RCT
NOAC monotherapy reduces net adverse clinical events in older patients with atrial fibrillation and stents NOAC Monotherapy Shows Lower Risk for Older Patients with Atrial Fibrillation
This post hoc analysis investigated the impact of NOAC monotherapy versus combination therapy with clopidogrel in patients with atrial fibri…
Patients over 75 with atrial fibrillation and drug-eluting stents may have fewer adverse events when taking a single NOAC instead of combina…
Aug 5, 2026
Apixaban reduces stroke and systemic embolism in patients with subclinical atrial fibrillation and an implantable cardiac monitor
Cardiology RCT
Apixaban reduces stroke and systemic embolism in patients with subclinical atrial fibrillation and an implantable cardiac monitor Apixaban reduces stroke risk in patients with certain heart conditions
This randomized controlled trial evaluated 4012 patients with subclinical atrial fibrillation, including a cohort of 209 with an implantable…
A new analysis shows that apixaban may significantly lower stroke risks for patients with subclinical atrial fibrillation and specific cardi…
Jul 3, 2026
Apixaban Reduces Intracranial Bleeding Risk Compared To Aspirin In Patients With Cryptogenic Stroke And Atrial Cardiopathy Evidence
Neurology RCT
Apixaban Reduces Intracranial Bleeding Risk Compared To Aspirin In Patients With Cryptogenic Stroke And Atrial Cardiopathy Evidence Trial shows apixaban reduces intracranial bleeding risk versus aspirin in cryptogenic stroke patients
In a multicenter randomized trial of 1,015 patients, apixaban demonstrated a significant reduction in intracranial hemorrhage compared to as…
A trial of 1,015 patients found apixaban caused fewer intracranial hemorrhages than aspirin, offering safety insights for those with cryptog…
Jun 1, 2026
Network meta-analysis compares DOACs and VKAs for intracranial hemorrhage risk
Cardiology Meta-analysis
Network meta-analysis compares DOACs and VKAs for intracranial hemorrhage risk Dabigatran may be safest for brain bleeding risk
This network meta-analysis of 127,267 patients with venous thromboembolism or atrial fibrillation found that all DOACs had lower risk of int…
All blood thinners beat warfarin for brain bleed risk, but dabigatran may be the safest choice.
Frontiers May 19, 2026
Meta-analysis finds lower bleeding risk with apixaban and rivaroxaban vs VKAs in dialysis patients with AF
Cardiology Meta-analysis
Meta-analysis finds lower bleeding risk with apixaban and rivaroxaban vs VKAs in dialysis patients with AF New Blood Thinners Cut Bleeding Risk For Dialysis Patients
This meta-analysis of observational studies and RCTs compared apixaban or rivaroxaban with vitamin K antagonists in dialysis patients with a…
New blood thinners could save lives for dialysis patients by cutting bleeding and stroke risks while waiting for bigger studies to confirm t…
May 14, 2026
PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications
Drug Pipeline Sys. Review
PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications Meals May Not Matter for Most New Heart and Diabetes Pills
This PRISMA scoping review synthesized data from 36 publications regarding food-drug interactions in cardiovascular and diabetic medications…
Most new heart and diabetes pills work the same whether you take them with food or on an empty stomach, but a few still need timing.
Frontiers Apr 27, 2026
Shorter fibrin clot lysis time linked to higher bleeding risk in atrial fibrillation patients on anticoagulants
Cardiology RCT
Shorter fibrin clot lysis time linked to higher bleeding risk in atrial fibrillation patients on anticoagulants Short clot breakdown time predicts higher bleeding risk
This RCT in 1,841 atrial fibrillation patients found that shorter pretreatment fibrin clot lysis time was associated with a significantly hi…
A simple blood test measuring how fast clots dissolve could help doctors spot patients at higher risk of bleeding before they even start tak…
Apr 22, 2026
Inflammatory and cardiac markers linked to VTE and bleeding risks in cancer patients on apixaban
Oncology RCT
Inflammatory and cardiac markers linked to VTE and bleeding risks in cancer patients on apixaban New Blood Tests May Predict Clot and Bleed Risks in Cancer
A post hoc analysis of an RCT in 574 ambulatory cancer patients with a Khorana score ≥2 found that elevated baseline growth differentiation …
Scientists found specific blood markers that signal higher risks of clots and bleeding in cancer patients.
Apr 22, 2026
Network meta-analysis compares prophylactic anticoagulants for central venous catheter-related thrombosis in cancer patients
Drug Pipeline Meta-analysis
Network meta-analysis compares prophylactic anticoagulants for central venous catheter-related thrombosis in cancer patients Cancer Patients May Avoid Clots With Safer Blood Thinner
This network meta-analysis synthesizes data from 19 clinical studies regarding prophylactic anticoagulation in cancer patients with central …
A new analysis shows one specific blood thinner may protect cancer patients from dangerous clots with fewer side effects.
Frontiers Apr 19, 2026
Apixaban Plasma Levels Elevated in Medicare Patients Taking CYP3A4 and P-gp Inhibitors
Drug Pipeline Cohort
Apixaban Plasma Levels Elevated in Medicare Patients Taking CYP3A4 and P-gp Inhibitors Higher Drug Levels Mean More Bleeding Risk
This pilot cohort study evaluated 35 Medicare patients with atrial fibrillation receiving apixaban 5mg BID.
Taking common heart rhythm drugs with apixaban raises blood levels and increases the risk of serious bleeding that can lead to hospitalizati…
medRxiv Apr 19, 2026
Genetic polymorphisms influence pharmacokinetics and bleeding risk for DOACs in meta-analysis
Cardiology Meta-analysis
Genetic polymorphisms influence pharmacokinetics and bleeding risk for DOACs in meta-analysis Your DNA May Explain Why Blood Thinners Work Differently for You
A meta-analysis of 39 studies involving 13,300 patients found that genetic polymorphisms (e.g., CES1, ABCB1) are associated with pharmacokin…
Tiny DNA differences may explain why the same blood thinner protects one person but causes bleeding in another.
Frontiers Apr 15, 2026

All apixaban Articles